Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company that develops drugs for the treatment of rare diseases. The company's lead drug candidate, Firdapse, is a treatment for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder that affects the neuromuscular junction. Catalyst Pharmaceuticals was founded in 2002 and is headquartered in Coral Gables, Florida. The company is committed to improving the lives of patients with rare diseases and advancing the science of drug development.